Search clinical trials for: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetax

Total 21 results

Guangdong Provincial People's Hospital

Completed

TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer (neoCARH)

HER2-Positive Breast Cancer

China
Guangdong Provincial People's Hospital
First Affiliated Hospital, Sun Yat-Sen University; Henan Cancer Hospital; Dongguan... and other collaborators

Completed

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Agendia
University of South Florida; University of Miami; University of Oklahoma; Ohio... and other collaborators

Completed

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (MINT)

Breast Cancer

United States
Henan Cancer Hospital

Withdrawn

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Shandong Cancer Hospital and Institute

Unknown

Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (BCSMANC)

Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Breast Cancer | Neoadjuvant Therapy | Hormone Receptor-positive Breast Cancer | HER2-low-expressing Breast Cancer

China
Sanofi

Completed

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

Breast Cancer

United States
Shengjing Hospital

Recruiting

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Stage II-III Breast Cancer

China
Georgetown University

Recruiting

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (RAGE)

Non-metastatic Breast Cancer | Cancer Related Cognitive Decline

United States
Fudan University

Recruiting

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

HER2 Positive Early Breast Cancer

China
University of Chicago

Not yet recruiting

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (TARMAC)

Triple Negative Breast Cancer
Fudan University

Recruiting

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (PANSY)

Breast Cancer

China
Karolinska University Hospital

Recruiting

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE)

Breast Cancer

Sweden
Renske Altena

Terminated

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (PREDIXIIHER2)

HER2-positive Breast Cancer | Early-stage Breast Cancer

Sweden
wang shusen

Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002)

Breast Neoplasms

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Adjuvant Treatment of Breast Cancer

Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Neoadjuvant Treatment of Breast Cancer

Breast Cancer

China
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.; Cancer International Research Group (CIRG)

Terminated

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

Breast Cancer

Korea, Republic of, United States, Canada, Spain, Ireland, Australia, Argentina, China, United Kingdom, Germany, Brazil, Hong Kong, France, Israel, Taiwan, Serbia, Belgium, Thailand, Croatia, Egypt, Italy, Philippines, Bosnia and Herzegovina and more
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
Washington University School of Medicine
Genentech, Inc.

Terminated

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Breast Neoplasms

United States
GlaxoSmithKline

Terminated

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (INDUCT)

Neoplasms, Breast

United States, Belgium, United Kingdom, Germany, Russian Federation, Italy, France

Search clinical trials for: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetax

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations